2022-2028 年全球骨肉瘤診斷和治療市場
市場調查報告書
商品編碼
1123113

2022-2028 年全球骨肉瘤診斷和治療市場

Global Bone Cancer Diagnosis and Therapeutics Market Research and Forecast 2022-2028

出版日期: | 出版商: Orion Market Research | 英文 136 Pages | 商品交期: 2-3個工作天內

價格

全球骨肉瘤診斷和治療市場規模預計在預測期內以 8.1% 的顯著複合年增長率增長。與佩吉特病相關的患者數量不斷增加,正在影響並成為推動市場發展的主要因素之一。此外,人均醫療費用的增加、幹細胞移植技術等也有望成為推動市場增長的主要因素。此外,研發和技術進步被認為是創造市場機會的一些因素。

本報告研究和分析全球骨肉瘤診斷和治療市場,提供市場概況、細分市場分析、競爭格局和主要參與者。

內容

第 1 章報告概述

第 2 章市場概述和注意事項

  • 調查範圍
  • 分析師見解和當前市場趨勢

第 3 章競爭格局

  • 主要公司分析
    • 概覽
    • 財務分析
    • SWOT 分析
    • 近期發展
  • 關鍵戰略分析
  • COVID-19 對主要公司的影響

第 4 章市場決定因素

  • 驅動程序
  • 限制因素
  • 機會

第 5 章市場細分

  • 全球骨肉瘤診斷和治療市場,按類型
    • 原發性骨肉瘤
    • 繼發性骨肉瘤
  • 全球骨肉瘤診斷和治療市場:按診斷
    • 核磁共振掃描
    • X 射線
    • CT 掃描
    • 放射性核素骨傳感器
    • 活檢
    • 其他
  • 全球骨肉瘤診斷和治療市場,按治療
    • 放射治療
    • 冷凍手術
    • 其他
  • 全球骨肉瘤診斷和治療市場,按最終用戶分類
    • 綜合醫院
    • 癌症研究中心

第六章區域分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 意大利
    • 西班牙
    • 法國
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他
  • 其他地區

第七章公司簡介

  • Amgen Inc.
  • Bayer AG
  • Bristol-Myers Squibb Co.
  • BeiGene
  • Eli lilly and company
  • F. Hoffmann-la roche ltd.
  • Infinity Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Koninklijke Philips N.V.
  • Merck & Co., Inc.
  • Merrion pharmaceuticals plc.
  • Novartis AG
  • Pfizer Inc.
Product Code: OMR2017198

Global Bone Cancer Diagnosis and Therapeutics Market Research By Type (Primary Bone Cancer and Secondary Bone Cancer), By Diagnosis (MRI Scans, X-Rays, CT-Scan, Radionuclide Bone Sensors, Biopsy and Other), By Therapies (Radiation Therapy, Cryosurgery and Other) and By End-User (Multispecialty Hospitals and Cancer Research Centers) Forecast 2021-2027

The global bone cancer diagnosis and therapeutics market is growing at a considerable CAGR of 8.1% during the forecast period. Rising number of incidences in individual related to Paget disease is one of the prime factors affecting and driving the market. Increasing per capita healthcare expenditure, technology for stem cell transplants among others is also estimated to be the key factors that are contributing significantly towards the growth of the market. However, lack of awareness in under developed nations with regards to diagnosis and therapeutics along with high cost involvement in treatment are some major factors constraints that are hindering the growth of the global bone cancer diagnosis and therapeutics market.

However, R&D and technological advancement are some of the key factors that are creating opportunities for the market. New product launches in the market are likely to drive the growth of the global bone cancer diagnosis and therapeutics market. For instance, in November 2020, BeiGene had officially notified the approval in China for its XGEVA (denosumab). This approval was received in China for the patients suffering due to bone metastasis from solid tumors along with patients having multiple myeloma in order to prevent skeletal-related events.

Impact of COVID-19 on the Global Bone Cancer Diagnosis and Therapeutics Market

The global bone cancer diagnosis and therapeutics market is hardly hit by the COVID-19 pandemic since December 2019. The COVID-19 pandemic in the major economies had disrupted manufacturing and transportation activities. Moreover, the operations and procedures related to surgery were also interrupted due to the COVID-19 pandemic that had adversely impacted the market.

Segmental Outlook

The market is segmented based on type, diagnosis, therapies and end-user. Based on by type, market is segmented into primary bone cancer and secondary bone cancer. By diagnosis, market is segmented into MRI scans, x-rays, CT-scan, radionuclide bone sensors, biopsy and other. Further by therapies the market is segmented into radiation therapy, cryosurgery and other. By end user the market is segmented into multispecialty hospitals and cancer research centers.

Global Bone Cancer Diagnosis and Therapeutics Market by Type 2020 (%)

Global Bone Cancer Diagnosis and Therapeutics Market by Type

Based on the type, primary bone cancer holds significant share in the market. It is a type of cancer that occurs and begins in the bone. It may occur to the patient on the surface, in the outer layer or it can be observed from the center of the bone. The treatment is very necessary if it is left untreated it can spread to other body parts. Further, According to Australian institute of health and wealth around 250 Australians every year are been diagnosed with primary bone cancer. More than 30 types of bone cancer are considered in this category; however most commonly observed includes Osteosarcoma, Chondrosarcoma and Ewing's sarcoma. This can be treated through surgery and various type of therapy given to patients.

Regional Outlooks

The global bone cancer diagnosis and therapeutics market is analyzed based on the geographical regions that are contributing significantly towards the growth of the market. Based on the geography, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America held a considerable share in 2020 in the global bone cancer diagnosis and therapeutics market. Some factors that are boosting the market growth in North America are high expenditure in healthcare along with increasing prevalence of bone cancer. Additionally, development in technology and research projects conducted in the region is other factor to driving the growth of the market. For instance, In February 2020, one of the organizations catalyzing research initiatives named as Count Me In has set forth the launch of the project that name as osteosarcoma project. This project is considered as patient -partnered effort that supports accelerating research work for people in countries that include the US and Canada those who have been affected by osteosarcoma.

Global Bone Cancer Diagnosis and Therapeutics Market, by Region 2021-2027

Global Bone Cancer Diagnosis and Therapeutics Market, by Region

Asia-Pacific will have Considerable Growth in the Global Bone Cancer Diagnosis and Therapeutics Market

Asia-Pacific region is expected to witness significant growth opportunities for the market. Increasing number of cancer patients along with growing geriatric population is likely to drive the growth of the regional market. Further, due to health availability, rising health care expenditure along with rising number of market player in India, China and South Korea are also some of the factors that are affecting and impacting the growth.

Market Player Outlook

Key players of the global bone cancer diagnosis and therapeutics market are Amgen Inc., Bayer AG, Merck & Co., Inc., Novartis AG, and Pfizer Inc. among others. To survive in the market, these players adopt different marketing strategies such as product launches and acquisition. For instance, in October 2020, Johnson & Johnson Services, had notified its acquisition of momenta pharmaceuticals, Inc. which is one of the companies that offers therapies. The acquisition was done for around $6.5 billion as this would play an important role for providing their assistance in advance patient care.

In September 2020, Bristol-Myers Squibb Co. had announced that the company has received approval and clearance from heath Canada for INREBIC. This would support in treating patients by offering them once in a day oral option who had been affected by rare bone marrow cancer. These new treatments would be helpful in effectively treating rare disorders.

The Report Covers

Market value data analysis of 2020 and forecast to 2027.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global bone cancer diagnosis and therapeutics market based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market-entry and market expansion strategies.

Competitive strategies by identifying 'who-stands-where in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Bone Cancer Diagnosis and Therapeutics Industry
  • Recovery Scenario of Global Bone Cancer Diagnosis and Therapeutics Industry
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments
  • 3.2. Key Strategy Analysis
  • 3.3. Impact of Covid-19 on Key Players

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Bone Cancer Diagnosis and Therapeutics Market by Type
    • 5.1.1. Primary Bone Cancer
    • 5.1.2. Secondary Bone Cancer
  • 5.2. Global Bone Cancer Diagnosis and Therapeutics Market by Diagnosis
    • 5.2.1. MRI Scans
    • 5.2.2. X-Rays
    • 5.2.3. CT-Scan
    • 5.2.4. Radionuclide Bone Sensors
    • 5.2.5. Biopsy
    • 5.2.6. Other
  • 5.3. Global Bone Cancer Diagnosis and Therapeutics Market by Therapies
    • 5.3.1. Radiation Therapy
    • 5.3.2. Cryosurgery
    • 5.3.3. Other
  • 5.4. Global Bone Cancer Diagnosis and Therapeutics Market by End User
    • 5.4.1. Multispecialty Hospitals
    • 5.4.2. Cancer Research Centers

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. South Korea
    • 6.3.5. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Amgen Inc.
  • 7.2. Bayer AG
  • 7.3. Bristol-Myers Squibb Co.
  • 7.4. BeiGene
  • 7.5. Eli lilly and company
  • 7.6. F. Hoffmann-la roche ltd.
  • 7.7. Infinity Pharmaceuticals, Inc.
  • 7.8. Johnson & Johnson Services, Inc.
  • 7.9. Koninklijke Philips N.V.,
  • 7.10. Merck & Co., Inc.
  • 7.11. Merrion pharmaceuticals plc.
  • 7.12. Novartis AG
  • 7.13. Pfizer Inc.

LIST OF TABLES

  • 1. GLOBAL BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS, 2020-2027 ($ MILLION)
  • 2. GLOBAL BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET BY TYPE,2020-2027($ MILLION)
  • 3. GLOBAL PRIMARY BONE CANCER MARKET BY REGION, 2020-2027($ MILLION)
  • 4. GLOBAL SECONDARY BONE CANCER MARKET BY REGION, 2020-2027 ($ MILLION)
  • 5. GLOBAL BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET BY DIAGNOSIS,2020-2027 ($ MILLION)
  • 6. GLOBAL MRI SCAN MARKET BY REGION, 2020-2027 ($ MILLION)
  • 7. GLOBAL X-RAYS MARKET BY REGION, 2020-2027 ($ MILLION)
  • 8. GLOBAL CT-SCAN MARKET BY REGION, 2020-2027 ($ MILLION)
  • 9. GLOBAL RADIONUCLIDE BONES SENSORS MARKET BY REGION, 2020-2027($ MILLION)
  • 10. GLOBAL BIOPSY MARKET BY REGION, 2020-2027($ MILLION)
  • 11. GLOBAL OTHER MARKET BY REGION, 2020-2027($ MILLION)
  • 12. GLOBAL BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET BY THERAPIES, 2020-2027($ MILLION)
  • 13. GLOBAL RADIATION THERAPY MARKET BY REGION, 2020-2027($ MILLION)
  • 14. GLOBAL CRYOSURGERY MARKET BY REGION, 2020-2027($ MILLION)
  • 15. GLOBAL OTHER MARKET BY REGION, 2020-2027($ MILLION)
  • 16. GLOBAL BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET BY END USER,2020-2027($ MILLION)
  • 17. GLOBAL MULTISPECIALTY HOSPITALS MARKET BY REGION, 2020-2027($ MILLION)
  • 18. GLOBAL CANCER RESEARCH INSTITUTE MARKET BY REGION, 2020-2027($ MILLION)
  • 19. GLOBAL BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET BY GEOGRAPHY, 2020-2027($ MILLION)
  • 20. NORTH AMERICAN BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)

21. NORTH AMERICAN BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TYPE,2020-2027($MILLION)

22. NORTH AMERICAN BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS,2020-2027($MILLION)

23. NORTH AMERICAN BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY THERAPY,2020-2027($MILLION)

24. NORTH AMERICAN BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY END USER,2020-2027($MILLION)

25. EUROPEAN BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY,2020-2027 ($MILLION)

26. EUROPEAN BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TYPE,2020-2027($MILLION)

27. EUROPEAN BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS,2020-2027($MILLION)

28. EUROPEAN BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY THERAPY,2020-2027 ($MILLION)

29. EUROPEAN BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY END USER,2020-2027($MILLION)

30. ASIA-PACIFIC BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY,2020-2027 ($MILLION)

31. ASIA-PACIFIC BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TYPE,2020-2027($MILLION)

32. ASIA-PACIFIC BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS,2020-2027($MILLION)

33. ASIA-PACIFIC BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY THERAPY,2020-2027($MILLION)

34. ASIA-PACIFIC BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY END USER,2020-2027($MILLION)

35. REST OF THE WORLD BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY TYPE,2020-2027($MILLION)

36. REST OF THE WORLD BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS,2020-2027($MILLION)

37. REST OF THE WORLD BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY THERAPY,2020-2027($MILLION)

38. REST OF THE WORLD BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY END USER,2020-2027($MILLION)

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBAL BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET, 2020-2027 ($ MILLION)
  • 2. IMPACT OF COVID-19 ON GLOBAL BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET BY SEGMENT, 2020-2027 ($ MILLION)
  • 3. RECOVERY OF GLOBAL BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET, 2021-2027 (%)
  • 4. GLOBAL BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET SHARE BY TYPE, 2020 VS 2027 (%)
  • 5. GLOBAL BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET SHARE BY DIAGNOSIS, 2020 VS 2027 (%)
  • 6. GLOBAL BONE CANCER DIAGNOSIS AND THERAPEUTICS SHARE BY THERAPIES, 2020 VS 2027 (%)
  • 7. GLOBAL BONE CANCER DIAGNOSIS AND THERAPEUTICS SHARE BY END USER, 2020 VS 2027 (%)
  • 8. GLOBAL BONE CANCER DIAGNOSIS AND THERAPEUTICS SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 9. GLOBAL PRIMARY BONE CANCER MARKET BY REGION, 2020 VS 2027 (%)
  • 10. GLOBAL SECONDARY BONE CANCER MARKET BY REGION, 2020 VS 2027 (%)
  • 11. GLOBAL MRI SCAN MARKET BY REGION, 2020 VS 2027 (%)
  • 12. GLOBAL X-RAYS MARKET BY REGION, 2020 VS 2027 (%)
  • 13. GLOBAL CT-SCAN MARKET BY REGION, 2020 VS 2027 (%)
  • 14. GLOBAL RADIONUCLIDE BONES SENSORS MARKET BY REGION, 2020 VS 2027 (%)
  • 15. GLOBAL BIOPSY MARKET BY REGION, 2020 VS 2027 (%)
  • 16. GLOBAL OTHER MARKET BY REGION, 2020 VS 2027 (%)
  • 17. GLOBAL RADIATION THERAPY MARKET BY REGION, 2020 VS 2027 (%)
  • 18. GLOBAL CRYOSURGERY MARKET BY REGION, 2020 VS 2027 (%)
  • 19. GLOBAL OTHER MARKET BY REGION, 2020 VS 2027 (%)
  • 20. GLOBAL MULTISPECIALTY HOSPITALS MARKET BY REGION, 2020 VS 2027 (%)
  • 21. GLOBAL CANCER RESEARCH INSTITUTE MARKET BY REGION, 2020 VS 2027 (%)
  • 22. US BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2020-2027 ($ MILLION)
  • 23. CANADA BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2020-2027 ($ MILLION)
  • 24. UK BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2020-2027 ($ MILLION)
  • 25. FRANCE BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2020-2027 ($ MILLION)
  • 26. GERMANY BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2020-2027 ($ MILLION)
  • 27. ITALY BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2020-2027 ($ MILLION)
  • 28. SPAIN BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2020-2027 ($ MILLION)
  • 29. REST OF EUROPE BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2020-2027 ($ MILLION)
  • 30. INDIA BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2020-2027 ($ MILLION)
  • 31. CHINA BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2020-2027 ($ MILLION)
  • 32. JAPAN BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2020-2027 ($ MILLION)
  • 33. SOUTH KOREA BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE,2020-2027 ($ MILLION)
  • 34. REST OF ASIA-PACIFIC BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2020-2027 ($ MILLION)
  • 35. REST OF THE WORLD BONE CANCER DIAGNOSIS AND THERAPEUTICS MARKET SIZE, 2020-2027 ($ MILLION)